The Protective Role of p53 in Ras-Induced Transformation of REF52 Cells

Molecular Biology

Volumn 37, Issue 3, 2003, Pages 392-403

  Kopnin, P B ^a,c   Ivanov, A V ^a   Il'inskaya, G V ^b   Sablina, A A ^b   Kopnin, B P ^b   Chumakov, P M ^a  

^a ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

^b N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

Cell cycle; Neoplastic transformation; p53; RAS

Indexed keywords

PROTEIN P21; PROTEIN P53; RAS PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL LINE; CELL NUCLEUS; CELL PROLIFERATION; CELL PROTECTION; CELL TRANSFORMATION; EMBRYO; EMBRYO CELL; FIBROBLAST; FUNCTIONAL MORPHOLOGY; NONHUMAN; ONCOGENE; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT;

ANIMALIA;

EID: 0038801507     PISSN: 00268933     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1024235310268     Document Type: Article

References (51)

1. Levine A.J. 1997. p53, the cellular gatekeeper for growth and division. Cell. 88, 323-331.
2. Giaccia A.J., Kastan M.B. 1998. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev. 12, 2973-2983.
3. Prives C., Hall P.A. 1999. The p53 pathway. J. Path. 187, 112-126.
4. Chumakov P.M. 2000. The function of the p53 gene: A choice between life and death. Biokhimiya. 65, 34-47.
5. Sionov R.V., Haupt Y. 1999. The cellular response to p53: the decision between life and death. Oncogene. 18, 6145-6157.
6. Vogelstein B., Lane D., Levine A. 2000. Surfing the p53 network. Nature. 408, 307-310.
7. el-Deiry W.S. 1998. Regulation of p53 downstream genes. Semin. Cancer Biol. 8, 345-357.
8. Donehower L.A., Harvey M., Slagle B.L., McArthur M.J., Montgomery C.A. Jr., Butel J.S., Bradley A. 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 356, 215-221.
9. Hollstein M., Soussi T., Thomas G., von Brevem M.C., Bartsch. 1997. p53 gene alterations in human tumors: perspectives for cancer control. Recent Results Cancer Res. 143, 369-389.
10. Hainaut P., Soussi T., Shomer B., Hollstein M., Greenblatt M., Hoving E., Harris C.C., Montesano R. 1997. Database of p53 gene somatic mutations in human tumors and cell lines: undated compilation and future prospects. Nucleic Acids Res. 1, 151-157.
11. Serrano M., Lin A.W., McCurrach M.E., Beach D., Lowe S.W. 1997. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell. 88, 593-602.
12. Lowe S.W. 1999. Activation of p53 by oncogenes. Endocrine-Related Cancer. 6, 45-48.
13. Woods D.B., Vousden, K.H. 2001. Regulation of p53 function. Exp. Cell Res. 264, 56-66.
14. Campbell S.L., Khosravi-Far R., Rossman K.L., Clark G.J., Der C.J. 1998. Increasing complexity of Ras signaling. Oncogene. 17, 1395-1413.
15. Bar-Sagi D., Hall A. 2000. Ras and Rho GTPases: a family reunion. Cell. 103, 227-238.
16. Malumbres M., Pellicer A. 1998. Ras pathways to cell cycle control and cell transformation. Front Biosci. 3, 887-912.
17. Crespo P., Leon J. 2000. Ras proteins in the control of the cell cycle and cell differentiation. Cell Mol. Life Sci. 57, 1613-1636.
18. Bos J.L. 1989. Ras oncogenes and human cancer: a review. Cancer Res. 49, 4682-4689.
19. Rodenhuis S. 1992. ras and human tumors. Semin. Cancer Biol. 3, 241-247.
20. Land H., Parada L.F., Weinberg R.A. 1983. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature. 304, 596-602.
21. Franza B.R., Maruyama K., Garrels J.I., Ruley H.E. 1986. In vitro establishment is not a sufficient prerequisite for transformation by activated ras oncogenes. Cell. 44, 409-418.
22. Hunter T. 1991. Cooperation between oncogenes. Cell. 64, 249-270.
23. Ragozzino M.M., Kuo A., DeGregori J., Kohl N., Ruley H.E. 1991. Mechanisms of oncogene cooperation: activation and inactivation of a growth antagonist. Environ. Health Perspect. 93, 97-103.
24. Hahn W.C., Weinberg R.A. 2002. Modelling the molecular circuitry of cancer. Nat. Rev. Cancer. 5, 331-341.
25. ARF links the tumour suppressor p53 to Ras. Nature. 395, 125-126.
26. Sherr C.J., Weber J.D. 2000. The ARF/p53 pathway. Curr. Opin. Genet. Dev. 10, 94-99.
27. Lin A.W., Barradas M., Stone J.C., van Aelst L., Serrano M., Lowe S.W. 1998. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev. 12, 3008-3019.
28. Zhu J., Woods D., McMahon M., Bishop J.M. 1998. Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev. 12, 2997-3007.
29. Pantoja C, Serrano M. 1999. Murine fibroblasts lacking p21 undergo senescence and are resistant to transformation by oncogenic Ras. Oncogene. 18, 4974-4982.
30. Kip1 without activating cyclin D-dependent kinases. J. Biol. Chem. 275, 27473-27480.
31. Hicks G.G., Egan S.E., Greenberg A.H., Mowat M. 1991. Mutant p53 tumor suppressor alleles release ras-induced cell cycle growth arrest. Mol. Cell. Biol. 11, 1344-1352.
32. Sage J., Mulligan G.J., Attardi L.D., Miller A., Chen S., Williams B., Theodorou E., Jacks T. 2000. Targeted disruption of the three Rb-related genes leads to loss of G(1) control and immortalization. Genes Dev. 14, 3037-3050.
33. Ruley H.E. 1990. Transforming collaborations between ras and nuclear oncogenes. Cancer Cells. 2, 258-268.
34. Hirakawa T., Ruley H.E. 1988. Rescue of cells from ras oncogene-induced growth arrest by a second, complementing, oncogene. Proc. Natl. Acad. Sci. USA. 85, 1519-1523.
35. Zerler B., Moran B., Maruyama K., Moomaw J., Grodzicker T., Ruley H.E. 1986. Adenovirus E1A coding sequences that enable ras and pmt oncogenes to transform cultured primary cells. Mol. Cell. Biol. 6, 887-899.
36. Kohl N.E., Ruley H.E. 1987. Role of c-myc in the transformation of REF52 cells by viral and cellular oncogenes. Oncogene. 2, 41-48.
37. Facchini M.L., Penn L.Z. 1998. The molecular role of Myc in growth and transformation: recent discoveries lead to new insights. FASEB J. 12, 633-651
38. Ferbeyre G., de Stanchina E., Querido E., Baptiste N., Prives C., Lowe S.W. 2000. PML is induced by oncogenic ras and promotes premature senescence. Genes Dev. 14, 2015-2027.
39. Ferbeyre G., de Stanchina E., Lin A.W., Querido E., McCurrach M.E., Hannon G.J., Lowe S.W. 2002. Oncogenic ras and p53 cooperate to induce cellular senescence. Mol. Cell. Biol. 10, 3497-3508.
40. Souyri M., Koehne C.F., O'Donnell P.V., Aldrich T.H., Furth M.E., Fleissner E. 1987. Biological effects of a murine retrovirus carrying an activated N-ras gene of human origin. Virology. 158, 69-78.
41. Morgenstern J.P., Land H. 1990. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 18, 3587-3596.
42. Ossovskaya V.S., Mazo I.A., Chernov M.V., Chernova O.B., Strezoska Z., Kondratov R., Stark G.R., Chumakov P.M., Gudkov A.V. 1996. Use of genetic suppressor elements to dissect distinct biological effects of separate p53 domains. Proc. Natl. Acad. Sci. USA. 93, 10 309-10 314.
43. Grignani F., Kinsella T., Mencarelli A., Valtieri M., Riganelli D., Lanfrancone L., Peschle C., Nolan G.P., Pelicci P.G. 1998. High-efficiency gene transfer and selection of human hematopoietic progenitor cells with a hybrid EBV/retroviral vector expressing the green fluorescence protein. Cancer Res. 58, 14-19.
44. Gossen M., Bujard H. 1992. Tight control of gene expression in mammalian cells by tetracycline-responsive promotors. Proc. Natl. Acad. Sci. USA. 89, 5547-5551.
45. Sambroock J., Fritsch E.F., Maniatis. T. 1989. Molecular Cloning: A Laboratory Manual, 2nd ed., N.Y., Cold Spring Harbor: Cold Spring Harbor Laboratory.
46. Lakin N.D., Jackson S.P. 1999. Regulation of p53 in response to DNA damage. Oncogene. 18, 7644-7655.
47. Kukushkin A.N., Svetlikova S.B., Belov D.N., Slepneva N.I., Pospelov V.A. 1996. Transcription factors C-ERB and AP-1 modulate the promoter activity of the regulatory region of the human p53 gene. Mol. Biol. 30, 93-103.
48. Kirch H.C., Flaswinkel S., Rumpf H., Brockmann D., Esche H. 1999. Expression of human p53 requires synergistic activation of transcription from the p53 promoter by AP-1, NF-kappaB and Myc/Max. Oncogene. 18, 2728-2738.
49. Lee M., Yu S., Park J.S. 2000. Characterization of a nuclear factor that binds to AP1-like element in the rat p53 promoter during liver regeneration. J. Cell Biochem. 80, 124-132.
50. Shaulian E, Karin M. 2001. AP-1 in cell proliferation and survival. Oncogene. 20, 2390-2400.
51. Sugrue, M.M., Shin D.Y., Lee S.W., Aaronson S.A. 1997. Wild-type p53 triggers a rapid senescence program in human tumor cells lacking functional p53. Proc. Natl. Acad. Sci. USA. 94, 9648-9653.